Effects of thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for liver disease safe or not?

Hepatology Research

Volumn 43, Issue 6, 2013, Pages 610-620

  Nozaki, Reiji ^a   Murata, Soichiro ^b   Nowatari, Takeshi ^a   Maruyama, Takehito ^a   Ikeda, Naoya ^a   Kawasaki, Takuya ^a   Fukunaga, Kiyoshi ^a   Ohkohchi, Nobuhiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Akt; Hepatocellular carcinoma; Huh7; MPL; Thrombopoietin

Indexed keywords

RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER REGENERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTOSIS; WESTERN BLOTTING;

EID: 84878809348     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12006     Document Type: Article

References (52)

1. Matsuo R, Ohkohchi N, Murata S etal. Platelets strongly induce hepatocyte proliferation with IGF-1 and HGF in vitro. J Surg Res 2008; 145: 279-286.
2. Kawasaki T, Murata S, Takahashi K etal. Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. J Hepatol 2010; 53: 648-654.
3. Myronovych A, Murata S, Chiba M etal. Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 2008; 49: 363-372.
4. Murata S, Ohkohchi N, Matsuo R, Ikeda O, Myronovych A, Hoshi R. Platelets promote liver regeneration in early period after hepatectomy in mice. World J Surg 2007; 31: 808-816.
5. Murata S, Matsuo R, Ikeda O etal. Platelets promote liver regeneration under conditions of Kupffer cell depletion after hepatectomy in mice. World J Surg 2008; 32: 1088-1096.
6. Watanabe M, Murata S, Hashimoto I etal. Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol 2009; 24: 78-89.
7. Ikeda N, Murata S, Maruyama T etal. Platelet-derived adenosine 5′-triphosphate suppresses activation of human hepatic stellate cell: In vitro study. Hepatol Res 2012; 42: 91-102.
8. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol 1990; 17: 198-209.
9. Cadili A, de Gara C. Complications of splenectomy. Am J Med 2008; 121: 371-375.
10. Sattler M, Durstin M, Frank D etal. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995; 23: 1040-1048.
11. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578-2584.
12. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89: 101-107.
13. Cardier JE, Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood 1998; 91: 923-929.
14. Schmelzer E, Deiwick A, Bruns H, Fiegel HC, Bader A. Thrombopoietin is a growth factor for rat hepatic progenitors. Eur J Gastroenterol Hepatol 2008; 20: 209-216.
15. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LAM. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 13-20.
16. Kawaguchi T, Komori A, Seike M etal. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol 2012 (in press).
17. Watanabe T, Shibata N, Westerman KA etal. Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation 2003; 75: 1873-1880.
18. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824.
19. Yuan F, Dellian M, Fukumura D etal. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-3756.
20. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55: 3509-3512.
21. Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16: 329-333.
22. Romanelli RG, Petrai I, Robino G etal. Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290: G120-128.
23. Erickson-Miller CL, Chadderton A, Gibbard A etal. Thrombopoietin receptor levels in tumor cell lines and primary tumors. J Oncol 2010; 2010: 135354.
24. Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981-988.
25. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors. Cancer 2007; 110: 477-488.
26. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells: From clinic to bench-a critical review. Biochim Biophys Acta 2010; 1806: 82-95.
27. Hardee ME, Cao Y, Fu P etal. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007; 2: e549.
28. Rosti V, Pedrazzoli P, Ponchio L etal. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993; 78: 208-212.
29. Selzer E, Wacheck V, Kodym R etal. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421-426.
30. Westphal G, Niederberger E, Blum C etal. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002; 88: 150-159.
31. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122: 1005-1011.
32. Wetzler M, Bernstein SH, Baumann H etal. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leuk Lymphoma 1998; 30: 415-433.
33. Brizzi MF, Battaglia E, Montrucchio G etal. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 1999; 84: 785-796.
34. Cardier JE. Effects of megakaryocyte growth and development factor (thrombopoietin) on liver endothelial cells in vitro. Microvasc Res 1999; 58: 108-113.
35. Matsumura I, Kanakura Y, Kato T etal. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 1995; 86: 703-709.
36. Motoji T, Takanashi M, Motomura S etal. Growth stimulatory effect of thrombopoietin on the blast cells of acute myelogenous leukaemia. Br J Haematol 1996; 94: 513-516.
37. Tafuri A, Lemoli RM, Petrucci MT etal. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Exp Hematol 1999; 27: 1255-1263.
38. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002; 13: 61-73.
39. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
40. Liu ZJ, Italiano J, Ferrer-Marin F etal. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood 2011; 117: 4106-4117.
41. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JFM. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008; 8: 187-198.
42. Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K. Cyclin D1 over-expression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3β and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003; 24: 435-442.
43. Chen B, Pan H, Zhu L, Deng Y, Pollard JW. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 2005; 19: 1978-1990.
44. Haga S, Ogawa W, Inoue H etal. Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J Hepatol 2005; 43: 799-807.
45. Faridi J, Fawcett J, Wang L, Roth RA. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation. Am J Physiol Endocrinol Metab 2003; 285: E964-972.
46. Latronico M, Costinean S, Lavitrano M, Peschle C, Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci 2004; 1015: 250-260.
47. Nakanishi K, Fujimoto J, Ueki T etal. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 1999; 17: 507-514.
48. McHutchison JG, Dusheiko G, Shiffman ML etal. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-2236.
49. Dultz G, Kronenberger B, Azizi A etal. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011; 55: 229-232.
50. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009; 37: 1030-1037.
51. Will B, Kawahara M, Luciano JP etal. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009; 114: 3899-3908.
52. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010; 34: 1224-1231.